| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |